242 related articles for article (PubMed ID: 27863143)
1. Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.
Elassaiss-Schaap J; Rossenu S; Lindauer A; Kang SP; de Greef R; Sachs JR; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):21-28. PubMed ID: 27863143
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.
Chatterjee MS; Elassaiss-Schaap J; Lindauer A; Turner DC; Sostelly A; Freshwater T; Mayawala K; Ahamadi M; Stone JA; de Greef R; Kondic AG; de Alwis DP
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):29-39. PubMed ID: 27896938
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Ahamadi M; Freshwater T; Prohn M; Li CH; de Alwis DP; de Greef R; Elassaiss-Schaap J; Kondic A; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):49-57. PubMed ID: 27863186
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.
de Greef R; Elassaiss-Schaap J; Chatterjee M; Turner DC; Ahamadi M; Forman M; Cutler D; de Alwis DP; Kondic A; Stone J
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):5-7. PubMed ID: 27653180
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
8. Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
Meneses-Lorente G; McIntyre C; Hsu JC; Thomas M; Jacob W; Adessi C; Weisser M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1239-1247. PubMed ID: 28497320
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
10. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
12. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
13. Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.
Rodríguez-Vera L; Ramos-Suzarte M; Fernández-Sánchez E; Soriano JL; Guitart CP; Hernández GC; Jacobo-Cabral CO; de Castro Suárez N; Codina HC
J Clin Pharmacol; 2015 Aug; 55(8):888-98. PubMed ID: 25760761
[TBL] [Abstract][Full Text] [Related]
14. Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.
Li TR; Chatterjee M; Lala M; Abraham AK; Freshwater T; Jain L; Sinha V; de Alwis DP; Mayawala K
Clin Pharmacol Ther; 2021 Jul; 110(1):200-209. PubMed ID: 33462831
[TBL] [Abstract][Full Text] [Related]
15. Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
Ogungbenro K; Patel A; Duncombe R; Nuttall R; Clark J; Lorigan P
Clin Pharmacol Ther; 2018 Apr; 103(4):582-590. PubMed ID: 28913853
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
McDermott J; Jimeno A
Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]